Hyloris Announces Extension of Footprint of Maxigesic® IV into South America
06 Maggio 2021 - 7:00AM
Broadening of the addressable market for Maxigesic IV in
Latin America and the Caribbean to 17 countries
Maxigesic IV has potential to combat the
opioid epidemic in pain management
Liège, Belgium
– 6 May 2021
– Hyloris Pharmaceuticals SA
(Euronext Brussels: HYL), a specialty biopharma company
committed to bringing innovative treatments that offer added value
to underserved patient populations, today announces that its
partner for Maxigesic IV, AFT Pharmaceuticals (“AFT”), has extended
its existing license and distribution agreement with Pharma Bavaria
International for the commercialisation of Maxigesic IV, a novel,
patented, non-opioid treatment for post-operative pain, in South
America.
The extended collaboration further builds on the
agreement signed with Pharma Bavaria in February 2020 for the
commercialisation of Maxigesic IV in 12 countries in Central
America. Following multiple licensing deals with strong local
players over the past 12 months, Maxigesic IV is now licensed in
>100 countries across the globe, including the major markets in
Europe and the U.S. The focus over the next 24 months will now
shift towards accelerating regulatory submissions and launches in
these territories.
Stijn Van Rompay, Chief Executive
Officer of Hyloris, commented: “We are pleased that AFT
has extended its existing agreement with Pharma Bavaria, a strong
international player that promotes and distributes innovative
pharmaceuticals in >45 countries, with focus on major growth
regions and emerging economies, and an existing portfolio of
hospital-based injectable pain medications. Today’s news further
demonstrates the urgent need for safer and more effective
non-opioid pain treatments in the post-operative hospital setting,
and the potential of Maxigesic IV to address that need.”
Globally, approximately 1.2 billion vials1 are
sold per year in the non-opioid analgesic space and the market for
pain medicines in Latin America is expected to grow at an average
annual rate of 3.5% until 2027.2
About
Maxigesic®
IV
Maxigesic IV has been developed under the
development collaboration agreement signed in 2012 between Hyloris
and AFT Pharmaceuticals. Maxigesic IV is a unique combination of
1000mg paracetamol with 300mg ibuprofen solution for infusion for
use post-operatively. Results from a randomised, double-blind,
placebo-controlled Phase 3 trial in 276 patients following bunion
surgery demonstrated that Maxigesic IV was well-tolerated and had a
faster onset of action and offered higher pain relief compared to
ibuprofen IV or paracetamol IV alone in the same doses. Moreover,
the superior analgesic effect of Maxigesic IV was supported by a
range of secondary endpoints, including reduced opioid consumption
compared to the paracetamol IV and ibuprofen IV treatment groups
(P<0.005)3. An additional exposure study has demonstrated
Maxigesic IV’s efficacy and safety in an expanded population group
over a longer treatment period4. Maxigesic IV is protected by
several granted and pending patent applications. The preparations
to submit a New Drug Application (NDA) to the Food and Drug
Administration (FDA) by AFT are progressing
well.
About Hyloris
Pharmaceuticals
Hyloris is a specialty biopharma company
identifying and unlocking hidden potential in existing medications
for the benefit of patients and the healthcare system. Hyloris
applies its knowhow and technological innovations to existing
pharmaceuticals and has built a broad proprietary product pipeline
that has the potential to offer significant advantages over
currently available alternatives. Hyloris currently has two
partnered, commercial-stage products: Sotalol IV for the treatment
of atrial fibrillation, and Maxigesic® IV, a non-opioid
post-operative pain treatment. The Company’s development strategy
primarily focuses on the FDA’s 505(b)2 regulatory pathway, which is
specifically designed for pharmaceuticals for which safety and
efficacy of the molecule have already been established. This
pathway can reduce the clinical burden required to bring a product
to market, and significantly shorten the development timelines and
reduce costs and risks. Hyloris is based in Liège, Belgium. For
more information, visit www.hyloris.com and follow-us on
LinkedIn.
For more information, please
contact Hyloris
Pharmaceuticals:
Marieke VermeerschVP Investor Relations and
Corporate CommunicationsM: +32 (0)479 490
603marieke.vermeersch@hyloris.com
Disclaimer and forward-looking
statements
Hyloris means “high yield, lower risk”, which
relates to the 505(b)(2) regulatory pathway for product approval on
which the Issuer focuses, but in no way relates or applies to an
investment in the Shares.Certain statements in this press release
are “forward-looking statements.” These forward-looking statements
can be identified using forward-looking terminology, including the
words "believes", "estimates," "anticipates", "expects", "intends",
"may", "will", "plans", "continue", "ongoing", "potential",
"predict", "project", "target", "seek" or "should", and include
statements the Company makes concerning the intended results of its
strategy. These statements relate to future events or the Company’s
future financial performance and involve known and unknown risks,
uncertainties, and other factors, many of which are beyond the
Company’s control, that may cause the actual results, levels of
activity, performance or achievements of the Company or its
industry to be materially different from those expressed or implied
by any forward-looking statements. The Company undertakes no
obligation to publicly update or revise forward-looking statements,
except as may be required by law.
1 IQVIA2 Research and Markets 2020 3 Daniels et al,
2019, Clinical Therapeutics4 Maxigesic IV Phase 3 study. Study ID
No AFT-MXIV-11. NCT04005755. Submitted for publication
- Hyloris Press Release Maxigesic IV South America
Grafico Azioni Hyloris Pharmaceuticals (EU:HYL)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Hyloris Pharmaceuticals (EU:HYL)
Storico
Da Apr 2023 a Apr 2024